Abstract
Pancreatic cancer is the third leading cause of cancer death in the United States, and the 5-year relative survival for patients diagnosed with pancreatic cancer is less than 10%. Early intervention is the key to a better survival outcome. Currently, there are no biomarkers that can reliably detect pancreatic cancer at an early stage or identify precursors that are destined to progress to malignancy. The National Cancer Institute in partnership with the Kenner Family Research Fund and the Pancreatic Cancer Action Network convened a Data Jamboree on Biomarkers workshop on December 5, 2016, to discuss and evaluate existing or newly developed biomarkers and imaging methods for early detection of pancreatic cancer. The primary goal of this workshop was to determine if there are any promising biomarkers for early detection of pancreatic cancer that are ready for clinical validation. The Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection, formed under the auspices of this workshop, will provide the common platform and the resources necessary for validation. Although none of the biomarkers evaluated seemed ready for a large-scale biomarker validation trial, a number of them had sufficiently high sensitivity and specificity to warrant additional research, especially if combined with other biomarkers to form a panel.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 135-141 |
| Number of pages | 7 |
| Journal | Pancreas |
| Volume | 47 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1 2018 |
Fingerprint
Keywords
- biomarkers
- early detection
- PDAC
- validation
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Hepatology
- Endocrinology
Cite this
Validation of Biomarkers for Early Detection of Pancreatic Cancer : Summary of the Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection Workshop. / Young, Matthew R.; Wagner, Paul D.; Ghosh, Sharmistha; Rinaudo, Jo Ann; Baker, Stuart G.; Zaret, Kenneth S.; Goggins, Michael S; Srivastava, Sudhir.
In: Pancreas, Vol. 47, No. 2, 01.02.2018, p. 135-141.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Validation of Biomarkers for Early Detection of Pancreatic Cancer
T2 - Summary of the Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection Workshop
AU - Young, Matthew R.
AU - Wagner, Paul D.
AU - Ghosh, Sharmistha
AU - Rinaudo, Jo Ann
AU - Baker, Stuart G.
AU - Zaret, Kenneth S.
AU - Goggins, Michael S
AU - Srivastava, Sudhir
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Pancreatic cancer is the third leading cause of cancer death in the United States, and the 5-year relative survival for patients diagnosed with pancreatic cancer is less than 10%. Early intervention is the key to a better survival outcome. Currently, there are no biomarkers that can reliably detect pancreatic cancer at an early stage or identify precursors that are destined to progress to malignancy. The National Cancer Institute in partnership with the Kenner Family Research Fund and the Pancreatic Cancer Action Network convened a Data Jamboree on Biomarkers workshop on December 5, 2016, to discuss and evaluate existing or newly developed biomarkers and imaging methods for early detection of pancreatic cancer. The primary goal of this workshop was to determine if there are any promising biomarkers for early detection of pancreatic cancer that are ready for clinical validation. The Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection, formed under the auspices of this workshop, will provide the common platform and the resources necessary for validation. Although none of the biomarkers evaluated seemed ready for a large-scale biomarker validation trial, a number of them had sufficiently high sensitivity and specificity to warrant additional research, especially if combined with other biomarkers to form a panel.
AB - Pancreatic cancer is the third leading cause of cancer death in the United States, and the 5-year relative survival for patients diagnosed with pancreatic cancer is less than 10%. Early intervention is the key to a better survival outcome. Currently, there are no biomarkers that can reliably detect pancreatic cancer at an early stage or identify precursors that are destined to progress to malignancy. The National Cancer Institute in partnership with the Kenner Family Research Fund and the Pancreatic Cancer Action Network convened a Data Jamboree on Biomarkers workshop on December 5, 2016, to discuss and evaluate existing or newly developed biomarkers and imaging methods for early detection of pancreatic cancer. The primary goal of this workshop was to determine if there are any promising biomarkers for early detection of pancreatic cancer that are ready for clinical validation. The Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection, formed under the auspices of this workshop, will provide the common platform and the resources necessary for validation. Although none of the biomarkers evaluated seemed ready for a large-scale biomarker validation trial, a number of them had sufficiently high sensitivity and specificity to warrant additional research, especially if combined with other biomarkers to form a panel.
KW - biomarkers
KW - early detection
KW - PDAC
KW - validation
UR - http://www.scopus.com/inward/record.url?scp=85040992686&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040992686&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000000973
DO - 10.1097/MPA.0000000000000973
M3 - Article
C2 - 29346214
AN - SCOPUS:85040992686
VL - 47
SP - 135
EP - 141
JO - Pancreas
JF - Pancreas
SN - 0885-3177
IS - 2
ER -